Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 359 across all filing types
Latest filing 2025-10-31 Major Shareholding Noti…
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Zawiadomienie od TFI Allianz Polska S.A. o zmianie udziału w ogólnej liczby głosów w PolTREG S.A. - Content (PL)
Major Shareholding Notification Classification · 100% confidence The document is a short notification from PolTREG S.A. informing the market that they received a notification from an investment fund regarding a change in their shareholding percentage (voting rights). This is a standard disclosure of a change in significant share ownership, which falls under the category of Major Shareholding Notification.
2025-10-31 Polish
Raport biegłego rewidenta z przeglądu sprawozdania finansowego
Audit Report / Information Classification · 100% confidence The document is a 'Raport Niezależnego Biegłego Rewidenta z Przeglądu' (Independent Auditor's Review Report) concerning the interim condensed financial statements of Poltreg S.A. for the period ending June 30, 2025. It explicitly states it is a review report conducted by an external auditor (UHY ECA Audyt Sp. z o.o.) and not the financial statements themselves. According to the filing definitions, standalone audit reports and results of regulatory reviews fall under the 'AR' (Audit Report / Information) category. H1 2025
2025-09-10 Polish
Sprawozdanie Zarządu z działalności za okres 6 miesięcy zakończony dnia 30 czerwca 2025 roku
Interim / Quarterly Report Classification · 100% confidence The document is a 'Sprawozdanie Zarządu z działalności' (Management Board Report on Activities) for PolTREG S.A. covering the period from 01.01.2025 to 30.06.2025. It contains detailed financial data, management commentary, business strategy, and operational highlights for the first half of the year. As it is a comprehensive report for a period shorter than a full fiscal year (half-year) containing substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2025
2025-09-10 Polish
Sprawozdanie finansowe za okres 6 miesięcy zakończony dnia 30 czerwca 2025 roku
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Śródroczne skrócone sprawozdanie finansowe' (Interim condensed financial report) for the period 01.01.2025 to 30.06.2025. It contains comprehensive financial statements, including the statement of comprehensive income, statement of financial position, statement of changes in equity, and cash flow statement, along with detailed explanatory notes. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-10 Polish
Warunkowe przyznanie patentu przez Koreański Urząd Patentowy w projekcie terapii opartych na CAR-TREG w leczeniu chorób neurodegeneracyjnych - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from PolTREG S.A. regarding the status of a patent application in South Korea for their CAR-TREG therapy. It provides a specific update on intellectual property and business development progress. Since it does not fit into specific categories like financial reports, board changes, or dividend announcements, and is a formal regulatory disclosure, it falls under the RNS category.
2025-09-03 Polish
Podanie pierwszemu pacjentowi terapii w ramach badania klinicznego fazy II w projekcie PreTreg (cukrzyca przedobjawowa typu 1) - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document is a regulatory filing (raport bieżący) issued by PolTREG S.A. regarding the progress of a clinical trial (PreTreg). It provides a status update on the administration of therapy to the first patient and details regarding the trial's scope, funding, and objectives. Since it is a specific regulatory announcement regarding company operations and clinical trial milestones that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2025-08-04 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.